AMG 319 is a drug developed by
Amgen which acts as an
inhibitor of the
phosphoinositide 3-kinase enzyme subtype
PI3Kδ. It was originally developed as an
anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as
rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-
cancer effects, and it has been put into
clinical trials to assess its safety and
tolerability in this application.[1][2]
Mechanism(s) of action
It is a potential
immunotherapy because blocking PI3Kδ (PI3K p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells.[3]p110δ inactivation in
regulatory T cells unleashes CD8+cytotoxic T cells.[4]
Clinical trials
Its first clinical trial was a phase I/II study in adults with relapsed or refractory
lymphoid malignancies.[5] This was due to run from 2011 to 2013.[citation needed]
^Cushing TD, Hao X, Shin Y, Andrews K, Brown M, Cardozo M, et al. (January 2015). "Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease". Journal of Medicinal Chemistry. 58 (1): 480–511.
doi:
10.1021/jm501624r.
PMID25469863.
^Clinical trial number NCT01300026 for "A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies" at
ClinicalTrials.gov